NBY Stock Overview Develops and sells eyecare and wound care products in the United States and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
NovaBay Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NovaBay Pharmaceuticals Historical stock prices Current Share Price US$0.53 52 Week High US$9.08 52 Week Low US$0.36 Beta 0.67 1 Month Change -22.19% 3 Month Change -24.84% 1 Year Change -93.27% 3 Year Change -99.89% 5 Year Change -99.93% Change since IPO -100.00%
Recent News & Updates
Consensus EPS estimates fall by 131% Nov 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10 RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million. Oct 30
Consensus revenue estimates decrease by 15%, EPS upgraded Aug 20
New major risk - Negative shareholders equity Aug 15
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 15 See more updates
Consensus EPS estimates fall by 131% Nov 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 10 RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million. Oct 30
Consensus revenue estimates decrease by 15%, EPS upgraded Aug 20
New major risk - Negative shareholders equity Aug 15
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 15
NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Aug 01 NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Jul 27
Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 Jul 12
NYSE American Accepts NovaBay Pharmaceuticals Plan of Compliance Jun 08
No longer forecast to breakeven Jun 07
NovaBay Pharmaceuticals Provides Non-Compliance Update May 30
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 10
NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024 Apr 20
Consensus EPS estimates upgraded to US$0.27 loss, revenue downgraded Apr 16
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 27 New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY). New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.
New minor risk - Share price stability Jan 31
NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft Sep 15
Consensus EPS estimates fall by 56% Aug 17
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 13
New minor risk - Profitability Aug 12
NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 09
Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023 Jul 08
Novabay Pharmaceuticals, Inc. Approves to Elect Mijia (Bob) Wu as Director Jun 16
NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price Jun 13
NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023 May 19
Consensus revenue estimates increase by 20% May 18
No longer forecast to breakeven May 13
NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023 Feb 02 Novabay Pharmaceuticals, Inc. Announces Executive Changes
Consensus forecasts updated Dec 01
Consensus EPS estimates fall by 57% Nov 23
Price target decreased to US$39.88 Nov 22
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 16
High number of new and inexperienced directors Nov 16
NovaBay Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 10
Novabay Pharmaceuticals, Inc. Announces Newest Addition to the Dermadoctor Picture Porefect Collection 15% Niacinamide Pore Minimizing Serum Oct 27
NovaBay Pharmaceuticals, Inc.’ Avenova and DERMAdoctor Products to be Featured During the October 11-12 Amazon Prime Early Access Sale Oct 11
NovaBay Pharmaceuticals Receives NYSE American Notice Regarding Low Share Price Oct 10
Consensus EPS estimates fall by 13% Sep 21
Price target decreased to US$2.80 Sep 20 NovaBay Pharmaceuticals, Inc. announced that it expects to receive $3.25 million in funding Sep 10
Consensus EPS estimates fall by 14% Aug 25
Price target decreased to US$2.98 Aug 24
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
NovaBay Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Novabay Pharmaceuticals, Inc. Announces Availability of Select Dermadoctor Products Jul 22
Consensus forecasts updated May 21
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 13 NovaBay Pharmaceuticals, Inc. Expands DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations May 10
NovaBay Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
High number of new and inexperienced directors Apr 27
NovaBay Pharmaceuticals, Inc. Introduces Hydrating Cleansing Oil to Its Dermadoctor Calm Cool + Corrected Product Line Apr 03
Full year 2021 earnings: EPS and revenues miss analyst expectations Apr 01
NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022 Mar 31
Novabay Pharmaceuticals Announces Changes to Its Board of Directors Jan 30
Novabay Pharmaceuticals Expands Its Eyecare Product Portfolio with the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms Jan 12
Forecast to breakeven in 2024 Jan 02
Novabay Pharmaceuticals, Inc. Announces DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance Dec 15
Chief Product Officer recently bought US$125k worth of stock Dec 08
Price target increased to US$3.10 Dec 02
Consensus forecasts updated Dec 02
Third quarter 2021 earnings released: US$0.051 loss per share (vs US$0.08 loss in 3Q 2020) Nov 13
Price target increased to US$2.85 Oct 07
Consensus EPS estimates fall to -US$0.16 Aug 19
Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2020) Aug 14
Senior Manager & Controller Wang Xu has left the company Jul 28
FDA Declines to Review the NovaBay Pharmaceuticals, Inc.’s Emergency Use Authorization Request for the Test Kits Jun 12
NovaBay Pharmaceuticals, Inc. Launches First of Several New Products to Expand Avenova Line May 18
Price target decreased to US$2.58 May 13
First quarter 2021 earnings released: US$0.036 loss per share (vs US$0.057 loss in 1Q 2020) May 09
We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth Mar 29
Full year 2020 earnings released: US$0.32 loss per share (vs US$0.48 loss in FY 2019) Mar 29
Consensus forecasts updated Mar 27
NovaBay Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 25, 2021 Mar 19
New 90-day high: US$1.23 Feb 09 Shareholder Returns NBY US Pharmaceuticals US Market 7D -6.6% -0.3% -2.7% 1Y -93.3% 7.9% 23.4%
See full shareholder returns
Return vs Market: NBY underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is NBY's price volatile compared to industry and market? NBY volatility NBY Average Weekly Movement 11.2% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: NBY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NBY's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Show more NovaBay Pharmaceuticals, Inc. Fundamentals Summary How do NovaBay Pharmaceuticals's earnings and revenue compare to its market cap? NBY fundamental statistics Market cap US$2.59m Earnings (TTM ) -US$17.55m Revenue (TTM ) US$13.84m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NBY income statement (TTM ) Revenue US$13.84m Cost of Revenue US$5.97m Gross Profit US$7.87m Other Expenses US$25.42m Earnings -US$17.55m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.59 Gross Margin 56.87% Net Profit Margin -126.75% Debt/Equity Ratio 4.8%
How did NBY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 07:48 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NovaBay Pharmaceuticals, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Stephen Dunn Dawson James Securities Pooya Hemami Desjardins Securities Inc.
Show 8 more analysts 
